Prevalence of Alopecia Areata in Saudi Arabia: Cross-Sectional Descriptive Study
- PMID: 32923306
- PMCID: PMC7486019
- DOI: 10.7759/cureus.10347
Prevalence of Alopecia Areata in Saudi Arabia: Cross-Sectional Descriptive Study
Abstract
Background Alopecia areata (AA) is a common autoimmune disorder worldwide that affects the hair. Population differences have been observed in disease prevalence and clinical features, but no studies have examined AA prevalence at a large scale. In Saudi Arabia, information is lacking about AA characteristics. Objectives A quantitative, observational, cross-sectional study was conducted to assess AA prevalence, characteristics, and gender differences in Saudi Arabia. Materials and methods The study has used a validated Arabic questionnaire that targeted Saudi Arabia residents with a history of AA. A validated Arabic questionnaire was used to target Saudi Arabia residents with a history of AA, and the data collection instrument and written informed consent were distributed on Twitter and Facebook after permission from the Institutional Review Board. Prior to the study, accuracy validation for correct diagnosis by participants was performed in a 50-volunteer pilot test, which indicated an acceptable level of 96% accuracy. The questionnaire included high-quality images of different AA types and the collected data focused on variables such as the age of onset, affected body parts, treatment type, and family history of AA. Results A total of 5,362 participants returned completed questionnaires, of whom 741 (13.8%) had experienced AA at least once in their lives. Most were aged 11-30 years (69%), and the mean age of diagnosis was 18.6 years. Thirty-six percent (36%) of those with AA reported having a first-degree relative with the disease, and cross-sectional prevalence was 5.2%. Three-hundred fifty-nine (359; 18.9%) males and 382 (11%) females had AA. Twenty-nine point four percent (29.4%) of AA patients recovered in less than three months of AA onset, and 59.4% recovered in less than one year. Conclusion AA prevalence in Saudi Arabia is higher than in Western countries with a lower age of onset than in the former. AA affected males more than females and the mean age of onset was lower in the latter. Both male gender and young age of onset implied a worse prognosis.
Keywords: alopecia; alopecia areata; hair; hair fall; hair loss.
Copyright © 2020, Al-ajlan et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023).Dermatol Ther (Heidelb). 2023 Oct;13(10):2129-2151. doi: 10.1007/s13555-023-00991-3. Epub 2023 Aug 9. Dermatol Ther (Heidelb). 2023. PMID: 37558830 Free PMC article. Review.
-
Prescription Pattern of Tofacitinib for Alopecia Areata Among the Dermatologists in Saudi Arabia: A Cross-Sectional Study.Cureus. 2023 Jun 15;15(6):e40445. doi: 10.7759/cureus.40445. eCollection 2023 Jun. Cureus. 2023. PMID: 37325685 Free PMC article.
-
Awareness, Beliefs, and Psychological Impact of Patients with Alopecia Areata in Saudi Arabia: A Multi-Center Study.Patient Prefer Adherence. 2024 Dec 20;18:2597-2607. doi: 10.2147/PPA.S486039. eCollection 2024. Patient Prefer Adherence. 2024. PMID: 39720634 Free PMC article.
-
Demographic and Clinical Features of 1,641 Patients with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis: A Single-Center Retrospective Study.Skin Appendage Disord. 2021 Jan;7(1):8-12. doi: 10.1159/000510880. Epub 2020 Oct 28. Skin Appendage Disord. 2021. PMID: 33614711 Free PMC article.
-
Epidemiology and burden of alopecia areata: a systematic review.Clin Cosmet Investig Dermatol. 2015 Jul 24;8:397-403. doi: 10.2147/CCID.S53985. eCollection 2015. Clin Cosmet Investig Dermatol. 2015. PMID: 26244028 Free PMC article. Review.
Cited by
-
Tofacitinib Treatment in Patients With Active COVID-19 Infection.Cureus. 2021 Sep 14;13(9):e17957. doi: 10.7759/cureus.17957. eCollection 2021 Sep. Cureus. 2021. PMID: 34660145 Free PMC article.
-
Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis.Dermatol Ther (Heidelb). 2024 Oct;14(10):2759-2769. doi: 10.1007/s13555-024-01260-7. Epub 2024 Sep 10. Dermatol Ther (Heidelb). 2024. PMID: 39254890 Free PMC article.
-
Quality of Life and the Presence of Depression Among Adults with Hair Loss in the South of Saudi Arabia.Psychol Res Behav Manag. 2022 Aug 4;15:1989-1996. doi: 10.2147/PRBM.S375247. eCollection 2022. Psychol Res Behav Manag. 2022. PMID: 35957760 Free PMC article.
-
Diagnosis and Management of Alopecia Areata: A Saudi Expert Consensus Statement (2023).Dermatol Ther (Heidelb). 2023 Oct;13(10):2129-2151. doi: 10.1007/s13555-023-00991-3. Epub 2023 Aug 9. Dermatol Ther (Heidelb). 2023. PMID: 37558830 Free PMC article. Review.
-
CD4, CD8 and natural killer cells are depressed in patients with alopecia areata: their association with disease activity.BMC Immunol. 2022 Mar 17;23(1):13. doi: 10.1186/s12865-022-00486-4. BMC Immunol. 2022. PMID: 35300587 Free PMC article.
References
-
- Epidemiologic and genetic characteristics of alopecia areata (part 1) Alzolibani A. https://pubmed.ncbi.nlm.nih.gov/22367375/ Acta Dermatovenerol Alp Pannonica Adriat. 2011;20:191–198. - PubMed
-
- Alopecia areata. Part 1: pathogenesis, diagnosis, and prognosis. Spano F, Donovan JC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569104/ Can Fam Physician. 2015;61:751–755. - PMC - PubMed
-
- Alopecia areata. Wasserman D, Guzman-Sanchez DA, Scott K, Mcmichael A. Int J Dermatol. 2007;7:121–131. - PubMed
-
- Alopecia areata update. Hordinsky M, Junqueira AL. https://www.scmsjournal.com/article/abstract/?id=20. Semin Cutan Med Surg. 2015;34:72–75. - PubMed
LinkOut - more resources
Full Text Sources